Additionally, it was observed that SRPX2 level of pancreatic cancer patients with stable disease and progressive disease after chemotherapy was above that before chemotherapy, while SRPX2 level of pancreatic cancer patients with partial remission after chemotherapy was lower than that before chemotherapy, suggesting that SRPX2 was closely associated with chemotherapeutic efficacy of pancreatic cancer patients. This evidence concerns the gene SRPX2 and pancreatic neoplasm.